STEM CELL THERAPEUTIC

MEDIPOST’s Stem Cell Drug ‘CARTISTEM’ Hits 5,000 Sales Mark

MEDIPOST Obtains Patent in US for its Next-Generation Stem Cell Culturing Technology

MEDIPOST Signs MOU with Canadian Public-Private Consortium Funded by the Government of Canada

MEDIPOST Obtains Patent in China for Its Brain Disease Treatment Technology that Uses Stem Cells

MEDIPOST Completes Phase 1 and 2 Clinical Trials with its Lung Disease Treatment Drug ‘PNEUMOSTEM’ in US

MEDIPOST Obtains Patent in US for its Arthritis Treatment Technique

MEDIPOST Obtains Patent in US for its Alzheimer’s Disease Treatment Drug

MEDIPOST receives US Patent for ‘PNEUMOSTEM’ for Treating Lung Disease

MEDIPOST Obtains Patent in China for its Alzheimer’s Disease Treatment Substance

MEDIPOST Obtains Patent in Canada for its ‘PNEUMOSTEM’ Used to Treat Lung Diseases

MEDIPOST Obtains Stem Cell Therapy Patent in Japan for Treating Alzheimer’s Disease

Singapore/Taiwan consecutively invited MEDIPOST to its stem cell forums